• 4 results in Exploration of Targeted Anti-tumor Therapy
    Sort by
    Latest
    Open Access
    Review
    Role of liquid biopsy for thoracic cancers immunotherapy
    Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the [...] Read more.
    Raimondo Di Liello ... Paloma Martín-Martorell
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:183–199
    DOI: https://doi.org/10.37349/etat.2020.00012
    This article belongs to the special issue Liquid Biopsy in Thoracic Cancer
    View:3369
    Download:60
    Open Access
    Review
    Integration of PARP-inhibitors in ovarian cancer therapy
    Poly-ADP-ribose polymerase inhibitors (PARP-I) represent one of the most attractive and promising class of biological agents studied both in relapsed ovarian cancer (OC) and in the advanced setting. [...] Read more.
    Antonella Pietragalla ... Gennaro Daniele
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:171–182
    DOI: https://doi.org/10.37349/etat.2020.00011
    View:2256
    Download:37
    Open Access
    Review
    An overview of the anti-cancer actions of Tanshinones, derived from Salvia miltiorrhiza (Danshen)
    Tanshinone is a herbal medicinal compound described in Chinese medicine, extracted from the roots of Salvia miltiorrhiza (Danshen). This family of compounds, including Tanshinone IIA and Tanshinone [...] Read more.
    Irum Naz ... Kwang Seok Ahn
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:153–170
    DOI: https://doi.org/10.37349/etat.2020.00010
    This article belongs to the special issue Targeting Transcription Factors for Cancer Therapy
    Open Access
    Review
    Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors
    Chronic lymphocytic leukemia is a common form of leukemia and is dependent on growth-promoting signaling via the B-cell receptor. The Bruton tyrosine kinase (BTK) is an important mediator of B-cell  [...] Read more.
    Rachael Arthur ... Graham Packham
    Published: June 29, 2020 Explor Target Antitumor Ther. 2020;1:131–152
    DOI: https://doi.org/10.37349/etat.2020.00009
    This article belongs to the special issue Proteolysis Targeting Chimera (PROTAC)
    View:7100
    Download:279